Sagimet Biosciences

Sagimet is Biopharmaceutical Company in California USA.

TVB-2640 is an oral, first-in-class inhibitor of FASN.

TVB-2640 is an oral, first-in-class inhibitor of FASN in clinical development.

The Lancet Gastroenterology & Hepatology

Denifanstat met the primary endpoint in a planned interim readout, with 67% of treated patients achieving ≥30% reductions.

FASN inhibitor TVB-2640 reverses multiple components of diet-induced non alcoholic steatohepatitis in mice treated.

3-V Biosciences, Inc. announced the appointment of Edward M. Connor, Jr., MD, as Chief Medical Officer on June 3, 2010 at California.

3-V Biosciences, Inc. announced the appointment of Merdad V. Parsey, MD, PhD as Chief Executive Officer on September 30, 2010 at Menlo Park, California.

3-V Biosciences announced the appointment of Stephen R. Brady to the post of Vice President, Corporate Development, Strategy & Operations.

3-v-biosciences a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush PacGrow Healthcare Conference

Sagimet is Fatty Acid Synthase Inhibitor, focuses on blocking fatty acid synthase (FASN) a key regulator of lipid synthesis its activity is increased in certain diseases such as in the liver

Careers Clinical Trial Manager (Contract/Contract to Perm) About Us: Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase […]

3-V Biosciences, Inc. announced Stephen R. Brady has been named as Chief Business Officer on February 10, 2011 at Menlo Park, California.

Chief Executive Officer, Chief Scientific Officer George Kemble, PhD joined Sagimet Biosciences (then known as 3-V) in August 2011.

Sagimet targets fatty acid synthase (FASN), a key regulator of lipid synthesis.

Sagimet offers a platform of proprietary, selective fatty acid synthase (FASN) inhibitors.

Sagimet develops fatty acid synthase (FASN) inhibitors targeting metabolic and fibrotic pathways.

Sagimet Biosciences is a clinical-stage pharmaceutical company.

Sagimet’s privacy policy outlines how it collects, processes, and shares user data.

Sagimet develops therapies to address unmet medical needs.